ATA75295A - Rekombinante poxviren mit fremd-dna in essentiellen regionen - Google Patents

Rekombinante poxviren mit fremd-dna in essentiellen regionen

Info

Publication number
ATA75295A
ATA75295A AT0075295A AT75295A ATA75295A AT A75295 A ATA75295 A AT A75295A AT 0075295 A AT0075295 A AT 0075295A AT 75295 A AT75295 A AT 75295A AT A75295 A ATA75295 A AT A75295A
Authority
AT
Austria
Prior art keywords
foreign dna
defective
poxvirus
essential regions
recombinant poxviruses
Prior art date
Application number
AT0075295A
Other languages
English (en)
Other versions
AT405292B (de
Inventor
Falko-Guenter Dr Falkner
Georg Dipl Ing Holzer
Friedrich Dr Dorner
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22885307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATA75295(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of ATA75295A publication Critical patent/ATA75295A/de
Application granted granted Critical
Publication of AT405292B publication Critical patent/AT405292B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT0075295A 1994-04-29 1995-05-02 Rekombinante poxviren mit fremd-dna in essentiellen regionen AT405292B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23539294A 1994-04-29 1994-04-29

Publications (2)

Publication Number Publication Date
ATA75295A true ATA75295A (de) 1998-11-15
AT405292B AT405292B (de) 1999-06-25

Family

ID=22885307

Family Applications (2)

Application Number Title Priority Date Filing Date
AT95919361T ATE298370T1 (de) 1994-04-29 1995-04-28 Rekombinante poxviren mit fremdenpolynukleotiden in wichtigen regionen
AT0075295A AT405292B (de) 1994-04-29 1995-05-02 Rekombinante poxviren mit fremd-dna in essentiellen regionen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT95919361T ATE298370T1 (de) 1994-04-29 1995-04-28 Rekombinante poxviren mit fremdenpolynukleotiden in wichtigen regionen

Country Status (10)

Country Link
US (2) US5766882A (de)
EP (1) EP0758397B1 (de)
JP (1) JP3911010B2 (de)
AT (2) ATE298370T1 (de)
AU (1) AU694519B2 (de)
CA (1) CA2188447C (de)
DE (1) DE69534289T2 (de)
DK (1) DK0758397T3 (de)
ES (1) ES2243937T3 (de)
WO (1) WO1995030018A2 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374768B1 (en) * 1990-09-25 2008-05-20 Xenova Research Limited Viral vaccines
KR100242671B1 (ko) * 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
US6365393B1 (en) * 1996-02-28 2002-04-02 Bayer Aktiengesellschaft Parapoxviruses containing foreign DNA, their production and their use in vaccines
US6428965B1 (en) * 1997-07-17 2002-08-06 The Johns Hopkins University Screening assays for the interaction of semaphorins and neuropilins
US20030158396A1 (en) * 1997-07-29 2003-08-21 Harold Kleanthous Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
AT406376B (de) 1998-01-16 2000-04-25 Immuno Ag Chimäres poxvirus enthaltend eine retrovirale vektorkomponente
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
ES2170622B1 (es) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
US7858559B2 (en) * 2000-11-17 2010-12-28 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
DE60116371T3 (de) * 2000-11-23 2016-11-17 Bavarian Nordic A/S Variante des modifizierten vaccinia ankara virus
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US20030104402A1 (en) * 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
AU2002255495A1 (en) * 2001-02-02 2002-08-19 University Of Rochester Methods of identifying regulator molecules
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
US20030148973A1 (en) * 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
DK2348119T3 (en) 2002-02-01 2017-08-21 Oxford Biomedica (Uk) Ltd Polycistronic lentiviral vector
DK1420822T4 (en) * 2002-04-19 2017-10-09 Bavarian Nordic As Modified vaccinia virus Ankara for vaccination of newborns
EP1434858B2 (de) * 2002-09-05 2018-12-19 Bavarian Nordic A/S Verfahren zur amplifikation von einem poxvirus in serumfreien verhältnissen
CA2530956A1 (en) * 2003-07-03 2005-03-03 Board Of Trustees Operating Michigan State University Expression of a recombinant transgene
WO2005028634A2 (en) * 2003-09-18 2005-03-31 Emory University Improved mva vaccines
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US20080053516A1 (en) * 2006-08-30 2008-03-06 Richard Allen Hayes Solar cell modules comprising poly(allyl amine) and poly (vinyl amine)-primed polyester films
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
EP2529754A1 (de) 2007-05-03 2012-12-05 Agency For Science, Technology And Research (A*star) An ein intrazellulares PRL-1- oder PRL-3-Polypeptid bindende Antikörper
WO2010071610A1 (en) 2008-12-19 2010-06-24 Agency For Science, Technology And Research (A*Star) Severe chikungunya biomarkers
UA114882C2 (uk) 2009-08-19 2017-08-28 Дау Аґросаєнсиз Елелсі Трансгенна рослина кукурудзи, стійка до гербіцидів, та спосіб її ідентифікації
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
GB201006405D0 (en) 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
AU2011305348A1 (en) 2010-09-23 2013-04-18 Baxter Healthcare Sa Recombinant viral vectors and methods for inducing an immune response to yellow fever virus
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
WO2013033092A2 (en) 2011-09-03 2013-03-07 Boehringer Ingelheim Vetmedica Gmbh Streptococcus suis pilus antigens
US20130171189A1 (en) * 2011-10-14 2013-07-04 University Of Connecticut Inducible and repressible vaccinia viruses with improved safety
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
ES2689878T3 (es) 2013-02-21 2018-11-16 Boehringer Ingelheim Vetmedica Gmbh Proteínas H5 del virus de la gripe H5N1 para su uso como un medicamento
US9987348B2 (en) 2013-09-25 2018-06-05 Zoetis Services Llc PCV2B divergent vaccine composition and methods of use
PL3063278T3 (pl) 2013-11-01 2018-08-31 Sementis Limited Wytwarzanie wektora wirusowego
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
GB201322574D0 (en) 2013-12-19 2014-02-05 Equigerminal Sa Retroviral peptides
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
KR20160132494A (ko) 2014-04-03 2016-11-18 베링거잉겔하임베트메디카인코퍼레이티드 돼지 유행성 설사 바이러스 백신
DK3198017T3 (da) * 2014-09-26 2021-04-12 Us Health Virusbaserede ekspressionsvektorer og anvendelser deraf
EP3234130B1 (de) 2014-12-19 2020-11-25 The Broad Institute, Inc. Verfahren zum profiling vom t-zell-rezeptor-repertoire
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
EP3261669B1 (de) 2015-02-25 2022-08-03 Memorial Sloan Kettering Cancer Center Verwendung von inaktiviertem nichtreplizierendem modified-vaccinia-ankara-virus (mva) als monoimmunotherapie oder in kombination mit immun-checkpoint-blockierungsmitteln für solide tumoren
CN116173193A (zh) 2015-04-17 2023-05-30 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
CR20200476A (es) 2015-05-20 2020-12-02 Dana Farber Cancer Inst Inc ANTÍGENOS COMPARTIDOS (Divisional 2017-0584)
TWI750122B (zh) 2015-06-09 2021-12-21 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
DE102015111756A1 (de) * 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor
BR112017028224A2 (pt) 2015-08-31 2018-09-11 Boehringer Ingelheim Vetmedica Gmbh composição, e, método para proteger um leitão contra uma doença associada a pestivírus.
AU2016323106A1 (en) 2015-09-16 2018-03-29 Boehringer Ingelheim Animal Health USA Inc. Salmonella Choleraesuis-Salmonella Typhimurium vaccines
SG11201807022XA (en) 2016-02-25 2018-09-27 Memorial Sloan Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
EP3419648A4 (de) 2016-02-25 2019-09-11 Memorial Sloan-Kettering Cancer Center Replikationskompetente abgeschwächte vaccinia-viren mit deletion der thymidinkinase mit und ohne expression von menschlichem flt3l oder gm-csf für die krebsimmuntherapie
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
CN109563143A (zh) 2016-08-02 2019-04-02 瓦西尼斯公司 在牛痘病毒/真核细胞中产生多核苷酸文库的改良方法
WO2018032057A1 (en) * 2016-08-19 2018-02-22 Sementis Limited Viral vaccines
CA3036293A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh New promoters
CN109715219B (zh) 2016-09-20 2024-03-01 勃林格殷格翰动物保健有限公司 犬腺病毒载体
EP3515480A1 (de) 2016-09-20 2019-07-31 Boehringer Ingelheim Vetmedica GmbH Neuer schweinegrippenimpfstoff
UY37406A (es) 2016-09-20 2018-03-23 Boehringer Ingelheim Vetmedica Gmbh Nuevo sitio de inserción orf70 de ehv
KR102669319B1 (ko) 2016-11-03 2024-05-28 베링거잉겔하임베트메디카게엠베하 돼지 파보바이러스에 대한 백신
MX2019005136A (es) 2016-11-03 2019-06-20 Boehringer Ingelheim Vetmedica Gmbh Vacuna contra el parvovirus porcino y el virus del sindrome respiratorio reproductivo porcino y metodos de produccion de esta.
EP3574116A1 (de) 2017-01-24 2019-12-04 The Broad Institute, Inc. Zusammensetzungen und verfahren zum nachweis einer mutanten variante eines polynukleotids
WO2018140766A2 (en) 2017-01-30 2018-08-02 Boehringer Ingelheim Vetmedica, Inc. Porcine coronavirus vaccines
EP3621646A4 (de) 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center Mutanten des vaccinia-virus für die krebsimmuntherapie
CA3068052A1 (en) 2017-07-12 2019-01-17 Boheringer Ingelheim Animal Health Usa Inc. Senecavirus a immunogenic compositions and methods thereof
KR20200057742A (ko) 2017-09-23 2020-05-26 베링거잉겔하임베트메디카게엠베하 파라믹소바이러스과 발현 시스템
WO2019092027A1 (en) 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Sapelovirus immunogenic compositions and uses thereof
CN111712575B (zh) 2018-02-23 2024-07-19 勃林格殷格翰动物保健有限公司 表达外源猫副粘病毒基因的重组病毒载体系统及由其制备的疫苗
MX2020009722A (es) 2018-03-19 2021-01-29 Boehringer Ingelheim Vetmedica Gmbh Nuevo sitio de insercion ul43 de ehv.
CN111867625A (zh) 2018-03-19 2020-10-30 勃林格殷格翰动物保健有限公司 具有失活ul18和/或ul8的新ehv
CA3091982A1 (en) 2018-03-26 2019-10-03 Boehringer Ingelheim Animal Health USA Inc. Method of producing an immunogenic composition
EP3852800A1 (de) 2018-09-20 2021-07-28 Boehringer Ingelheim Vetmedica GmbH Intranasaler vektorimpfstoff gegen epidemische virusdiarrhoe
WO2020058327A1 (en) 2018-09-20 2020-03-26 Boehringer Ingelheim Vetmedica Gmbh Modified pedv spike protein
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
WO2021158878A1 (en) 2020-02-06 2021-08-12 Boehringer Ingelheim Animal Health USA Inc. Polypeptides useful for detecting anti-rhabdovirus antibodies
JP2023528805A (ja) 2020-05-26 2023-07-06 ディオニス セラピューティクス インコーポレイテッド 核酸人工ミニプロテオームライブラリー
CA3195910A1 (en) 2020-10-05 2022-04-14 Boehringer Ingelheim Vetmedica Gmbh Fusion protein useful for vaccination against rotavirus
US20220160864A1 (en) 2020-10-05 2022-05-26 Boehringer Ingelheim Animal Health USA Inc. Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries
GB202117405D0 (en) 2021-12-02 2022-01-19 Univ London Queen Mary Peptide
US20240050555A1 (en) 2022-04-05 2024-02-15 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition useful for vaccination against rotavirus
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5174993A (en) * 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5364773A (en) * 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5155020A (en) * 1989-03-08 1992-10-13 Health Research Inc. Recombinant poxvirus host range selection system
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5225336A (en) * 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
CH682669A5 (fr) * 1989-03-08 1993-10-29 Health Research Inc Virus recombinant modifié pour exprimer un produit de gènes chez un hôte, procédés et vaccin correspondants.
GB8907468D0 (en) * 1989-04-03 1989-05-17 Smith Geoffrey L Vaccinia vectors,vaccinia genes and expression products thereof
AU634773B2 (en) * 1989-05-08 1993-03-04 Basil Arif Spheroidin dna isolate and recombinant entomopoxvirus expression vectors
US5204243A (en) * 1990-02-14 1993-04-20 Health Research Incorporated Recombinant poxvirus internal cores
JP3895366B2 (ja) * 1990-09-25 2007-03-22 キャンタブ ファーマシューティカルズ リサーチ リミティド ウィルス ワクチン
GB9023352D0 (en) * 1990-10-26 1990-12-05 Lynxvale Ltd Vaccinia vectors,vaccinia genes and expression products thereof
US5989561A (en) * 1991-03-07 1999-11-23 Virogenetics Corporation Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses
US5843456A (en) * 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
US5997878A (en) * 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
KR100242671B1 (ko) * 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
US5863542A (en) * 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
ES2212795T3 (es) * 1991-08-26 2004-08-01 Baxter Healthcare S.A. Virus de la viruela de las aves de corral recombinante.
ATE288483T1 (de) * 1992-07-30 2005-02-15 Akzo Nobel Nv Nicht-verbreitendes lebendes herpesvirusvakzin
JPH10512151A (ja) * 1995-01-13 1998-11-24 ヴァイロジェネティクス コーポレイション Ｈｔｌｖ抗原を発現する組換え弱毒化ポックスウイルスを含有する免疫原性組成物

Also Published As

Publication number Publication date
WO1995030018A2 (en) 1995-11-09
JP3911010B2 (ja) 2007-05-09
WO1995030018A3 (en) 1996-01-04
EP0758397A1 (de) 1997-02-19
CA2188447C (en) 2002-10-22
JPH09512707A (ja) 1997-12-22
ATE298370T1 (de) 2005-07-15
DK0758397T3 (da) 2005-10-10
DE69534289D1 (de) 2005-07-28
DE69534289T2 (de) 2006-04-27
US5766882A (en) 1998-06-16
EP0758397B1 (de) 2005-06-22
US5770212A (en) 1998-06-23
AU694519B2 (en) 1998-07-23
CA2188447A1 (en) 1995-11-09
AT405292B (de) 1999-06-25
AU2523095A (en) 1995-11-29
ES2243937T3 (es) 2005-12-01

Similar Documents

Publication Publication Date Title
ATA75295A (de) Rekombinante poxviren mit fremd-dna in essentiellen regionen
MX164250B (es) Metodo mejorado para producir un vector de expresion de baculovirus recombinante
NL300257I2 (nl) Transgene dieren die gewenste eiwitten in de melk afscheiden.
DE3853088D1 (de) Rekombinantes Avipoxvirus.
DE69734930D1 (de) Adenovirales fiberprotein mit einem kurzen schaft und seine verwendung
DE3850019D1 (de) Rekombinantes Avipoxvirus.
DE68927511D1 (de) DNS-Sequenzen, die Polypeptiden mit beta-1,3-Glukanase-Aktivität codieren
ES2163864T3 (es) Secuencias de dna de 2-desoxiglucosa-6-fosfato (2-dog-6-p) como marcador de seleccion en plantas.
DE69031389D1 (de) Schnelle, vielseitige und einfache methode zur expression von genen in eukaryotischen zellen
ES8500322A1 (es) Un metodo de modificar un virus para conferirle una nueva funcion biologica.
DE3786592D1 (de) Transformation von trichoderma.
DE3382837T2 (de) Herstellung von funktionellen, menschlichen Urokinaseproteinen
DK156592A (da) Human-h1-praeprorelaxin, -prorelaxin og -relaxin samt polypeptid med relaxinaktivitet og fremgangsmaade til sammenfoejning af a- og b-kaederne i human-h1-relaxin
HU9201746D0 (en) Recombinant avipox virus, the virus infected cell cultivation and the vaccine resulted from it for poultry vaccination
WO1994002611A3 (en) Recombinant human erythropoietin with altered biological activity
NO891587L (no) Fremgangsmaate for fremstilling av proteinholdig materialeved dyrking av celler som inneholder rekombinante avipoxvirusvektorer.
ATE252153T1 (de) Rekombinanter birnavirusimpfstoff
EP0236977A3 (de) Impfstoffe gegen Rindervirus-Diarrhoe und Schweine-Cholera
EP0256677A3 (de) Pseudorabiesvirus-Rekombinanten und ihre Verwendung zur Herstellung von Proteinen
DE60036555D1 (de) Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter
DE69333074D1 (de) Rekombitante, equine herpesviren
ATE286509T1 (de) Interferon alpha/beta bindendes protein, seine herstellung und anwendung
FI963755A (fi) Glutamaatti-dekarboksylaasi-aktiivisuutta (GAD-aktiivisuutta) koodaavat yhdistelmä-DNA-tekniset virukset
NO864742D0 (no) Dna-sekvens som koder for human vevsplasminogenaktivator, rekombinant dna-sekvens, vertcelle transformert med denne samt fremgangsmaate for fremstilling av plasminogenaktivatoren.
ATE166880T1 (de) Impfstoff gegen cholera

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee
ELJ Ceased due to non-payment of the annual fee